Abbott Secures U.S. FDA Authorization for its Libre Duo 10 Day System

In August 2026, Abbott announced U.S. FDA authorization of its Libre Duo 10 Day system, the first dual glucose‑ketone sensing technology globally. The new wearable offers real-time glucose monitoring while detecting rising ketone levels that can lead to a diabetic ketoacidosis (DKA) emergency, helping diabetes management by preventing additional mental or physical burden for people with diabetes.

New Era of Early Detection and Health Monitoring  

Libre Duo 10 Day has received De Novo authorization from the FDA and is represented as the first system to meet the integrated continuous glucose monitoring (iCGM) and integrated continuous glucose and ketone monitoring (iCGK) standards. This innovation further aims to help people access vital medical technologies faster.

Diabetic ketoacidosis (DKA) is also considered a common and serious complication for people with diabetes, with hospital admissions rising 55% over the past decade. DKA can develop rapidly with requiring ketone monitoring, which many individuals lack access to. Dr. Jennifer Sherr also emphasized the importance of early detection, focusing that Abbott's dual glucose-ketone system can provide timely alerts for rising ketone levels too.

How does Libre Duo 10 Day Work?

Libre Duo 10 Day continuously monitors both glucose and ketone levels, and alerts when ketones rise. According to Chris Scoggins from Abbott, if glucose is the speedometer, ketones are like the check engine light. The system targets individuals with Type 1 or Type 2 diabetes who use insulin or certain medications, offering up to 10 days of wear and connectivity with the broader Libre digital health ecosystem.

Abbott is collaborating with leading pump companies to integrate Libre Duo 10 Day with automated insulin delivery systems, expecting compatibility with various devices by 2027. Dr. Aaron J. Kowalski from Breakthrough T1D highlights that this technology can significantly improve the management of elevated ketone levels and potentially prevent dangerous complications like DKA and support their management too.

Impact on the Healthcare Industry

This newly authorized Libre Duo 10 Day system positively impacts the industry by offering a first-of-its-kind tracking of both glucose and ketone levels simultaneously through a single dashboard, as a leap forward for medical technology.

The introduction of the Libre Duo 10 Day significantly changes chronic disease management from reactive to proactive, establishing new regulatory standards as the first device to meet both the FDA’s iCGM and the new iCGK standards. Abbott's integration with automated insulin delivery (AID) systems accelerates dosing accuracy and aligns with the FDA’s Home as a Healthcare Hub Initiative, moving advanced diagnostics into daily life.

The Libre Duo addresses major healthcare challenges, including increasing hospital admissions for Diabetic Ketoacidosis (DKA), which have surged 55% in the last decade. By offering automatic alerts for rising ketones, it aims to lower emergency room visits and costs. It continuously tracks ketones in real-time, eliminating the gaps of traditional blood tests and accelerating patient compliance by automating the ketone testing process.

Impact on the Diabetes Care Devices Industry

The global diabetes care devices market size is calculated at USD 68.57 billion in 2025 and is predicted to increase from USD 72.86 billion in 2026 to approximately USD 125.03 billion by 2035, expanding at a CAGR of 6.19% from 2026 to 2035.

According to Precedence Research, this authorization will benefit the industry by introducing the first wearable tool that tracks both blood sugar and ketones at the same time and bridges a critical gap in ketone monitoring by offering required health data.

Overall, in the diabetes care devices industry, the Libre Duo sets a new federal standard (iCGK) for ketone monitoring by promoting partnerships with smart pump manufacturers and pressures competitors like Dexcom and Medtronic to innovate. It also simplifies patient care by eliminating the need for manual tests and reduces stress by integrating glucose and ketone monitoring into one device, lowering both mental and physical burdens.

About Abbott

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. Abbott is a global leader in cardiovascular care, diabetes management, diagnostic testing, nutrition, pain and movement disorders, and more. Additionally, partnerships and strong awareness of chronic disease prevention and other issues impact global health.

Abbott’s major goal is to help people live fuller and healthier lives through the enabling power of health. The company focuses on turning science into lasting health solutions and expanding access to care worldwide.